A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2017
Price : $35 *
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novo Nordisk
- 15 Feb 2017 Results of post hoc analysis from pooled data of six trials (NCT02035371, NCT01924637, NCT02131246, NCT02033239, NCT02003677 and NCT01618188) published in the Clinical Pharmacokinetics
- 04 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.